Eli Lilly & Co. (LLY) February weekly 250 straddle priced for a move of +/- 3.5% into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
February 3, 2022 7:13 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales (beat versus FactSet for Trulicity, Taltz, Jardiance and Verzenio, among other... More
